Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Noelly Maria Zimpel, Trecenti"'
Autor:
Alexandre R Marra, João Luiz Miraglia, Daniel Tavares Malheiros, Yang Guozhang, Vanessa Damazio Teich, Elivane da Silva Victor, João Renato Rebello Pinho, Adriana Cypriano, Laura Wanderly Vieira, Miria Polonio, Rafael Herrera Ornelas, Solange Miranda de Oliveira, Flavio Araujo Borges Junior, Silvia Cristina Cassiano Oler, Guilherme de Paula Pinto Schettino, Ketti Gleyzer de Oliveira, Rúbia Anita Ferraz Santana, Fernanda de Mello Malta, Deyvid Amgarten, Ana Laura Boechat, Noelly Maria Zimpel Trecenti, Takaaki Kobayashi, Jorge L Salinas, Michael B Edmond, Luiz Vicente Rizzo
Publikováno v:
Clinical Infectious Diseases. 76:e360-e366
Background Little is currently known about vaccine effectiveness (VE) for either 2 doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac (Instituto Butantan) inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c018c9d135bc719f304380b4fe6a827c
https://doi.org/10.1093/cid/ciac430
https://doi.org/10.1093/cid/ciac430
Autor:
Alexandre R. Marra, João Luiz Miraglia, Daniel Tavares Malheiros, Yang Guozhang, Vanessa Damazio Teich, Elivane da Silva Victor, João Renato Rebello Pinho, Adriana Cypriano, Laura Wanderly Vieira, Miria Polonio, Rafael Herrera Ornelas, Solange Miranda de Oliveira, Flavio Araujo Borges Junior, Audrey Rie Ogawa Shibata, Guilherme de Paula Pinto Schettino, Ketti Gleyzer de Oliveira, Rúbia Anita Ferraz Santana, Fernanda de Mello Malta, Deyvid Amgarten, Ana Laura Boechat, Noelly Maria Zimpel Trecenti, Takaaki Kobayashi, Jorge L. Salinas, Michael B. Edmond, Luiz Vicente Rizzo
Publikováno v:
Infection Control & Hospital Epidemiology. 44:75-81
Objective:We investigated real-world vaccine effectiveness for Oxford-AstraZeneca (ChAdOx1) and CoronaVac against laboratory-confirmed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers (HCWs).Methods:We cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60e9ccaa5e39a229e031b726a0c61b8a
https://doi.org/10.1017/ice.2022.50
https://doi.org/10.1017/ice.2022.50
Autor:
Alexandre R, Marra, João Luiz, Miraglia, Daniel Tavares, Malheiros, Yang, Guozhang, Vanessa Damazio, Teich, Elivane, da Silva Victor, João Renato Rebello, Pinho, Adriana, Cypriano, Laura Wanderly, Vieira, Miria, Polonio, Rafael Herrera, Ornelas, Solange Miranda, de Oliveira, Flavio Araujo, Borges Junior, Audrey Rie Ogawa, Shibata, Guilherme de Paula Pinto, Schettino, Ketti Gleyzer, de Oliveira, Rúbia Anita, Ferraz Santana, Fernanda, de Mello Malta, Deyvid, Amgarten, Ana Laura, Boechat, Noelly Maria Zimpel, Trecenti, Takaaki, Kobayashi, Jorge L, Salinas, Michael B, Edmond, Luiz Vicente, Rizzo
Publikováno v:
Infection control and hospital epidemiology.
We aimed to investigate real-world vaccine effectiveness (VE) for Oxford-AstraZeneca (ChAdOx1) and CoronaVac against laboratory-confirmed COVID-19 infection among healthcare workers (HCWs).We conducted a retrospective cohort study among HCWs (aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9fdd2f2bd59106c72b487f33b22ba92b
https://pubmed.ncbi.nlm.nih.gov/35351217
https://pubmed.ncbi.nlm.nih.gov/35351217
Autor:
Alexandre R, Marra, João Luiz, Miraglia, Daniel Tavares, Malheiros, Yang, Guozhang, Vanessa Damazio, Teich, Elivane, da Silva Victor, João Renato Rebello, Pinho, Adriana, Cypriano, Laura Wanderly, Vieira, Miria, Polonio, Rafael Herrera, Ornelas, Solange Miranda, de Oliveira, Flavio Araujo, Borges Junior, Silvia Cristina Cassiano, Oler, Guilherme, de Paula Pinto Schettino, Ketti Gleyzer, de Oliveira, Rúbia Anita Ferraz, Santana, Fernanda, de Mello Malta, Deyvid, Amgarten, Ana Laura, Boechat, Noelly Maria Zimpel, Trecenti, Takaaki, Kobayashi, Jorge L, Salinas, Michael B, Edmond, Luiz Vicente, Rizzo
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Little is currently known about vaccine effectiveness (VE) for either two doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d8c14af790aab49d9621c720e73c31fe
https://pubmed.ncbi.nlm.nih.gov/35639918
https://pubmed.ncbi.nlm.nih.gov/35639918